Correction of Glycogen Synthase Kinase 3 <i>β</i> in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice
Mei Wang(Shihezi University), Lubov Timchenko(Cincinnati Children's Hospital Medical Center), Geneviève Gourdon(Inserm), Wen‐Chin Weng(National Taiwan University Hospital), Diana M. Lindquist(Cincinnati Children's Hospital Medical Center), Nikolai A. Timchenko(Cincinnati Children's Hospital Medical Center), Mike Snape(AMO Pharma (United Kingdom)), Lauren Stock(Cincinnati Children's Hospital Medical Center), Ana Martı́nez(Consejo Superior de Investigaciones Científicas)
Cited by 46
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
Identification of a (CUG)n Triplet Repeat RNA-Binding Protein and Its Expression in Myotonic Dystrophy
|Nucleic Acids Research|1996|460
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
CCAAT/enhancer-binding protein alpha (C/EBP alpha) inhibits cell proliferation through the p21 (WAF-1/CIP-1/SDI-1) protein.
|Genes & Development|1996|391
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348